T2 Biosystems, Inc. reiterated revenue guidance for the full year 2024. For the year, the company expects total sepsis and related product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 million in 2023. The Company?s 2024 revenue guidance consists entirely of sepsis product revenue and does not include potential sales of the T2Biothreat Panel or the T2Lyme Panel.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.375 USD | +1.98% | -7.11% | -29.24% |
May. 15 | Sector Update: Health Care Stocks Advance Late Wednesday Afternoon | MT |
May. 15 | T2 Biosystems Shares Rise After CRG Servicing Ups Stake | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.24% | 73.21M | |
+8.80% | 222B | |
+13.54% | 195B | |
+23.50% | 148B | |
+32.95% | 113B | |
+4.18% | 66.45B | |
+13.19% | 53.11B | |
+3.16% | 50.03B | |
-4.59% | 38.8B | |
-2.04% | 34.85B |
- Stock Market
- Equities
- TTOO Stock
- News T2 Biosystems, Inc.
- T2 Biosystems, Inc. Reiterates Revenue Guidance for the Full Year 2024